兰索拉唑(Lansoprazole) - 药物靶点：Proton pump_在研适应症：胃灼热，慢性胃炎，消化性溃疡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Agopton、DakaR、Lansoprazole (JP17/USP/INN)

+ [31]

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [3]

在研适应症

胃灼热慢性胃炎消化性溃疡+ [11]

非在研适应症

胃肠道溃疡痛风幽门螺杆菌感染+ [1]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Pfizer Australia Pty Ltd.Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceutical Co., Ltd.

+ [3]

非在研机构

Wyeth AB

最高研发阶段批准上市

首次获批日期

日本 (1992-10-02),

吻合口溃疡十二指肠溃疡胃溃疡+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H14F3N3O2S

InChIKeyMJIHNNLFOKEZEW-UHFFFAOYSA-N

CAS号103577-45-3

关联

207

项与兰索拉唑相关的临床试验

NCT06931223

/ Not yet recruitingN/AIIT

Efficacy of Gut-rain Neuromodulators in the Treatment of Functional Dyspepsia: a Randomized Controlled Study

The use of Neuromodulators is now recognized by international consensus as effective in improving Disorders of Gut-Brain Interaction (DGBIs). However, the digestive mind-body concept of therapeutic drugs is still in the experience-based treatment stage, and there is a lack of clinical studies in the field of DGBIs. Although numerous studies have been conducted to confirm the safety of Neuromodulators for the treatment of DGBIs, the current functional dyspepsia (FD) treatment is still awaiting further explorations and accumulations. In addition, neuromodulators, like Flupentixol-Melitracen (FM), are often used as a second-line treatment option for FD after the failure of acid-suppressive therapy with proton pump inhibitors, etc. However, the efficacy of conventional drugs for FD is mediocre, which often leads to recurrent and prolonged symptoms, seriously affecting patients' confidence in treatment and their quality of life, and the repeated visits to the clinic also create a huge economic burden for the society. Therefore, we conducted a clinical trial to verify whether FM can be used as the first-line therapy to improve the efficacy of FD patients.

开始日期2025-04-10

申办/合作机构-

ChiCTR2500098499

/ Suspended临床4期IIT

Effects of TDF/3TC/ANV on cardiovascular disease risk score and intestinal microecology in HIV-1 patients with dyslipidemia

开始日期2025-03-10

申办/合作机构

中国医科大学附属第一医院

IRCT20180620040164N66

/ SuspendedN/A

Bioequivalence study of ?Lansoprazole 30 mg Capsule of Dorsa Pharmaceutical Co. and Agopton of Takeda as reference in 24 healthy male under fasting.

开始日期2024-08-06

申办/合作机构-

100 项与兰索拉唑相关的临床结果

登录后查看更多信息

100 项与兰索拉唑相关的转化医学

登录后查看更多信息

100 项与兰索拉唑相关的专利（医药）

登录后查看更多信息

6,731

项与兰索拉唑相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

24-month outcomes after switching to Dolutegravir/Lamivudine in people living with HIV and HBcAb positivity at the Beijing Ditan Hospital in China

Article

作者: Zhao, Hongxin ; Biao, Ruojia ; Liu, Ying ; Chen, Jing ; Fu, Jiantao

BACKGROUND:

Dolutegravir/lamivudine (DTG/3TC) is a recommended therapy regimen for hepatitis B surface antigen (HBsAg)-negative people living with HIV (PLWH) who have achieved HIV virological suppression or are treatment-naïve. However, this may overlook the impact of occult hepatitis B infection on HIV suppression, which mainly present as hepatitis B core antibody (HBcAb) positive but HBsAg negative. We aim to assess the effect of HBcAb positivity on HIV suppression among PLWH who had switched to DTG/3TC.

METHODS:

A retrospective study was conducted including 127 HBcAb-positive and 474 HBcAb-negative PLWH (all were HBsAg negative) who had switched to DTG/3TC at the Beijing Ditan Hospital in China. HIV-RNA suppression was compared pre-switch (not baseline), at switch, and at 12&24 months post-switch, across three categories: (1) target not detected (TND); (2) HIV RNA < 40 cp/mL; (3) blip. Virological suppression included TND and HIV RNA < 40 cp/mL. Epidemiological (gender, age) and clinical data (CD4 count, HIV viral load, etc.) were extracted from the hospital information system. A p-value < 0.05 was considered statistically significant.

RESULT:

HBcAb-positive PLWH were older at DTG/3TC switch (median age: 41 vs. 36 years old, p < 0.001) and had lower nadir CD4 counts (median nadir CD4 counts: 255 vs. 295, p = 0.011). No difference in TND and HIV RNA < 40 cp/mL was present in the two groups at the switch (HBcAb-positive and -negative: 86.6% vs. 88.8%, 12.6% vs. 10.5%, p = 0.789). Similar HBcAb-positive compared with -negative PLWH resulted in TND at 12&24 months post-switch: 91.4% vs. 91% (p = 0.522) and 88.4% vs. 92.7% (p = 0.249), respectively. Consistent result was observed in HIV RNA < 40 cp/mL.

CONCLUSION:

In the 24-month follow-up after switching to DTG/3TC, HBcAb positivity was not significantly associated with HIV virological suppression.

2025-05-01·JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia

Article

作者: Cretella, Silvia ; Rigamonti, Claudio ; Colangeli, Vincenzo ; Bon, Isabella ; Giglia, Maddalena ; Viale, Pierluigi ; Calza, Leonardo

Background::

Dual regimen dolutegravir/lamivudine (DOL/3TC) showed potent efficacy and favorable safety in both antiretroviral therapy-naive and therapy-experienced patients, but data from real life about naive people with high-level viremia are still lacking.

Methods::

We performed a retrospective cohort study of people living with HIV who were naive to antiretroviral therapy, had baseline HIV-1 RNA ranging from 100,000 to 500,000 copies/mL, and initiated DOL/3TC. Virologic efficacy and changes in immunologic parameters after 12 months of treatment were evaluated and compared with highly viremic people living with HIV who started a triple antiretroviral combination.

Results::

Inclusion criteria were met by 58 patients with median age of 43.4 years. At baseline, mean HIV RNA was 5.4 log10 and mean CD4 T lymphocyte count was 488 cells/mm3. HIV RNA <50 copies/mL was obtained in 45 patients (77.6% in the intention-to-treat analysis) after 6 months and in 53 patients (91.4%) after 12 months. Reasons for treatment failure were virologic failure in 2 cases and adverse events in 3 cases. No significant changes in median value of lipids were reported, while there was a not significant increase in body weight (+1.18 kg). Virologic and immunologic response at month 12 in patients on DOL/3TC was comparable with that observed in 50 naive patients with high-level viremia and starting a triple antiretroviral therapy.

Conclusions::

In this real-life cohort of naive patients with high-level viremia, DOL/3TC was associated with high virologic efficacy and good tolerability after 12 months, supporting use of this dual regimen also in persons with high initial viremia.

2025-05-01·PEDIATRIC INFECTIOUS DISEASE JOURNAL

Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms

Article

作者: Sirikutt, Pugpen ; Rungsapphaiboon, Athiporn ; Tawan, Monta ; Tawon, Yardpiroon ; Phasomsap, Chayapa ; Puthanakit, Thanyawee ; Anugulruengkitt, Suvaporn ; Wacharachaisurapol, Noppadol ; Na Nakorn, Yossawadee ; Songtaweesin, Wipaporn Natalie ; Cressey, Tim R.

We investigated the steady-state pharmacokinetics of generic abacavir (ABC)/lamivudine (3TC) dispersible tablets (DTs) in young children living with HIV aged 3 months to <7 years, weighing 6 to <20 kg. Twenty-eight Thai children were enrolled and received ABC/3TC-DT plus pediatric dolutegravir-DT once daily. ABC/3TC was administered using WHO weight band (WB) doses: 180/90 mg, 240/120 mg and 300/150 mg for children weighing 6 to <10 kg (WB 1, n = 7), 10 to <14 kg (WB2, n = 9) and 14 to <20 kg (WB3, n = 12), respectively. ABC geometric mean (GM) AUC0–24 h (CV%) was 14.2 (50.5%), 15.6 (32.6%) and 20.7 (28.3%) mg.h/L, respectively, and 3TC GM AUC0–24 h was 14.8 (44.1%), 18.2 (28.0%) and 19.9 (26.2%) mg.h/L, respectively. ABC and 3TC exposures were within target ranges across WBs. These data supported current ABC/3TC-DT WHO-weight band dosing guidance for young children in Thailand.

205

项与兰索拉唑相关的新闻（医药）

2025-04-09

·药筛

抑酸药市场的下一战

消化系统用药中，抑酸药是大品种的摇篮。早期的H2受体拮抗剂，西咪替丁、雷尼替丁、法莫替丁都是当年的热销品种。后来，质子泵抑制剂上市，凭借绝对碾压的疗效优势，很快就成为市场主导，诞生了奥美拉唑、艾司奥美拉唑、兰索拉唑等全球重磅药品。特别是在国内市场，多个PPI类药物百花齐放，撑起将近400亿市场规模，培育了罗欣、奥赛康、扬子江、丽珠等专注PPI类药物的企业。数据来源：摩熵医药然而，随着国采不断推进，主流PPI类药物陆续被国采，仿制药价格大幅下降，注射剂单价从50多元，下降到个位数，口服剂型也只剩几毛钱一片，整体市场缩水一半。奥美拉唑、泮托拉唑、兰索拉唑、艾司奥美拉唑等，逐步从医院畅销药榜单中消失。质子泵抑制剂医院市场TOP10排名，2024年H1相比2018年，已彻底换了个样。数据来源：摩熵医药相关企业排名方面，丽珠凭借艾普拉唑的强劲表现，2024年H1医院市场销售，断层式遥遥领先。数据来源：摩熵医药在集采政策影响下，抑酸药市场，已经风光不再，但面对巨大的市场规模，企业不会轻言退出。于是，大家发起了新一轮的市场争夺战。首先是H2拮抗剂药物。准入属性完美的法莫替丁、雷尼替丁，还有非医保的罗沙替丁，抓住政策空档期，老树发新芽，销售额暴涨，成就了一批企业和代理商。数据来源：摩熵医药不过随着罗沙替丁被国采，法莫替丁多家企业过评，国采在即，外加全国价格治理，这一波市场热度，预计很快就会消退。其次是PPI类复方制剂拉唑类单方口服制剂太卷，就有企业就开发复方制剂。最早获批的是奥美拉唑碳酸氢钠胶囊，此后又有奥美拉唑碳酸氢钠干混悬、兰索拉唑碳酸氢钠胶囊、艾司奥美拉唑碳酸氢钠胶囊获批。但是，受医保准入以及适应症限制，此类产品的总销售额在2021年达到高峰后，就开始下降，2023年医院市场不足1亿元，这在巨大的抑酸药市场里，已无足轻重。数据来源：摩熵医药第三个是PPI的异构体艾司奥美拉唑剔除了奥美拉唑的R型异构体，只保留S型异构体，取得了巨大成功。于是，其它PPI也可以如法炮制。右旋兰索拉唑和左旋泮托拉唑就是国内企业的重点开发目标。2022年，南京优科的注射用右兰索拉唑首家获批，2024年奥赛康第二家获批，产品也通过国谈进入医保，但由于价格较低，市场销售并不理想，2024年上半年，医院市场销售不足600万元，未来增长潜力有限。而左旋泮托拉唑，虽有企业提交上市申请，但此产品还需要三期临床，离产品获批上市还有较长时间。数据来源：摩熵药筛小程序最后，有钱的企业，都来卷P-CAB抑制剂。P-CAB抑制剂也就是钾离子竞争性酸阻滞剂，作用机制为竞争性结合壁细胞内H+/K+-ATP酶（质子泵）的钾离子结合部位，阻止胃酸分泌。相比拉唑类PPI药物，疗效上略有优势。国内已有多个企业，瞄准了这类产品。伏诺拉生伏诺拉生是全球首个上市P-CAB抑制剂，由武田和大冢联合开发，2015年最早在日本获批，2019年获批进口，2020年进入医保后快速放量，2023年医院市场销售额已超过6亿元。数据来源：摩熵药筛小程序国内仿制药企业快速跟进，一拥而上，目前已有10多个仿制获批，还有140多个上市申请处在审评中。可以想象，等到2026年原研专利到期，市场竞争会是什么格局！数据来源：摩熵药筛小程序需要关注的是，在今年3月，柯菲平独家提交了注射液2类新药上市申请，这个要是能获批，倒是非常有竞争力。数据来源：摩熵药筛小程序替戈拉生2015年，罗欣从韩国的HK inno.N公司，买了替戈拉生片的国内市场开发权益，2022年获批上市，当年就通过医保谈判。2024年上半年医院市场销售超过1亿元。凯普拉生凯普拉生片是有柯菲平开发，销售权给了复星医药，2023年2月获批上市，市场销售刚刚起步。利那拉生2024年12月，上海生诺的戊二酸利那拉生酯胶囊获批上市。这个品种是贵州生诺医药从瑞典的Cinclus Pharma引进，后来又卖给了上海医药。获批适应症是反流性食管炎，市场也刚刚起步。另外扬子江药业买了韩国大熊的非苏拉生片，2023年报产，预计很快也能获批。丽珠买了韩国Onconic的Zastaprazan（又名为JP-1366），目前还在三期临床中。未来，P-CAB抑制剂必将是抑酸药的主战场。用摩熵药筛小程序，随时查询新产品！

临床3期核酸药物申请上市医药出海

2025-04-07

·cincluspharma.com

New scientific article highlights good healing results for Cinclus Pharma's drug candidate linaprazan glurate for the treatment of eGERD

Cinclus Pharma AB (publ), a developer of drugs for the treatment of gastric acid-related diseases, announced today that a scientific article has been published with data from a phase II study showing high healing rates for patients with severe forms of erosive gastroesophageal reflux disease, eGERD. The results support the continued development of linaprazan glurate as a next-generation drug for gastric acid-related diseases. The article, titled Randomised Controlled Trial: A Dose-Finding Study of Linaprazan glurate, A Novel Potassium Competitive Acid Blocker, vs. Lansoprazole for the Treatment of Erosive Esophagitis, has been published online in the scientific journal Alimentary Pharmacology & Therapeutics and is written by Prateek Sharma, Michael Vaezi, Peter Unge, Kjell Andersson, Kajsa Larsson, Ivan Popadiyn, Maria Rosenholm, Andras Rosztóczy, Elham Yektaei and David Armstrong. The published article presents data from a phase II clinical trial in which the treatment with linaprazan glurate (the next generation of PCAB) showed a high healing rate among patients suffering from eGERD. For patients who were not healed after eight weeks of treatment with proton pump inhibitor, the best-performing dose of linaprazan glurate achieved a 100 percent healing rate after four weeks, a higher rate of 28 percentage points compared to the treatment with the proton pump inhibitor lansoprazole. The healing rate for patients with moderate to severe eGERD was 93 percent, which was 50 percentage points higher than the treatment with lansoprazole. The results support the continued development of linaprazan glurate as a next-generation drug for gastric acid-related diseases. "The study shows very good healing rates, both for patients previously treated with PPI without being healed and for patients with severe eGERD, which highlights the potential of our drug candidate. We look forward to initiating the phase III program of linaprazan glurate during 2025”, says Kajsa Larsson, Chief Medical Officer at Cinclus Pharma. "The results show how effective treatment with linaprazan glurate is compared to today's standard treatment, and in extension also the first generation of PCAB. Cinclus Pharma's drug meets the medical need of the patients who suffer the most with the severe forms of eGERD, which constitutes a large market with blockbuster potential," said Christer Ahlberg, CEO of Cinclus Pharma. To access the article, please click the following link: http://doi.org/10.1111/apt.70109 For additional information, please contact: Christer Ahlberg, CEO Phone: +46 70 675 33 30 e-mail: christer.ahlberg@cincluspharma.com Henrik Vikström, IR Phone: +46 70 952 80 06 e-mail: henrik.vikström@cincluspharma.com About Cinclus Pharma Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com. Attachments New scientific article highlights good healing results for Cinclus Pharma's drug candidate linaprazan glurate for the treatment of eGERD

临床2期临床结果临床3期

2025-03-27

·摩熵医药

质子泵抑制剂市场：从百亿到腰斩，泮托拉唑缩水85%，雷贝拉唑登顶TOP1

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。在质子泵抑制剂市场持续变化的浪潮中，泮托拉唑、雷贝拉唑、艾司奥美拉唑等药物的表现备受关注。曾经百亿规模的泮托拉唑跌落神坛，雷贝拉唑却逆势成为市场 TOP1 品种，艾司奥美拉唑在原研与仿制的博弈中不断调整市场地位，艾普拉唑也凭借自身优势崭露头角。这些药物的市场竞争格局呈现出复杂多样的态势。本文将基于摩熵咨询《质子泵抑制剂市场专题研究报告》，全面而深入探索质子泵抑制剂市场竞争发展以及背后的商业逻辑。 01 具有更高稳定性的质子泵抑制剂——泮托拉唑 01 百亿品种跌落神坛，市场降幅超85% 泮托拉唑是全球上市的第三个质子泵抑制剂，与奥美拉唑相比具有较高的选择性和生物利用度，弱酸条件下稳定性优于奥美拉唑和兰索拉唑。泮托拉唑最早由BydGulden（现为日本武田制药的子公司）开发，1994年在德国、墨西哥上市，上市剂型为肠溶片。国内上市销售剂型主要为肠溶片、肠溶胶囊和注射剂，根据摩熵医药数据库统计显示，整体市场在2019年销售额达到了102亿元，但在注射剂与肠溶片进入集采后市场大幅下降，到2023年已经下降至14亿元，较2019年相比下降超过85%。泮托拉唑在售企业近百家，竞争激烈，TOP3企业为中美华东、九典制药和武田，占比分别为19.5%、11.5%和8.8%。图片来源：摩熵咨询《质子泵抑制剂市场专题研究报告》 02 肠溶片3家企业中选，销售额与销售量占比增长均超过50% 注射用泮托拉唑被纳入第四批国家集中采购，奥赛康、扬子江、中美华东等六家企业中选，平均降幅为88.49%。集采后中标企业销售额占比增加了8.15%，销售量占比增加了31.43%。泮托拉唑肠溶片被纳入第四批国家集中采购，九典制药、康恩贝和Aurobindo三家企业中选，平均降幅为57.91%。集采后中标企业销售额占比增加了55.10%，销售量占比增加了59.57%。 02 质子泵抑制剂市场”顶流” ——雷贝拉唑 01 质子泵抑制剂TOP1品种，2023年销售额达56亿元雷贝拉唑原研企业为卫材和强生，于1997年在日本获批上市。雷贝拉唑与质子泵结合位点多，代谢为非酶代谢，具有起效更快、个体化差异较小、与其他药物联用时相互作用少等优势。国内上市销售主要剂型为肠溶胶囊、肠溶片及注射剂。根据摩熵医药数据库统计显示，2023年雷贝拉唑销售额55.79亿元，虽然较前几年有所降低，但因降幅较小，因此整体市场为居于所有质子泵抑制剂首位。济川药业是雷贝拉唑领军企业，市场份额超30%，其胶囊剂市场规模最大，且具有绝对优势。图片来源：摩熵咨询《质子泵抑制剂市场专题研究报告》雷贝拉唑肠溶片纳入第九批国家集采，安必生制药、新华制药、海斯制药、山香药业、济川药业、九典制药、润都制药和药友制药八家企业中选。肠溶胶囊及注射剂因参比制剂尚不明确，目前一致性评价进程缓慢。 02 雷贝拉唑各级医院市场分析（以北京市为例）据摩熵医药药物流向数据显示，以北京市为例，雷贝拉唑2023年各季度销售量和销售额如下图：雷贝拉唑2023年销售额TOP3医院（北京市为例）分别为中国医学科学院肿瘤医院、首都医科大学附属北京安贞医院、中国医学科学院阜外医院。雷贝拉唑2023年销售市场主要分布在三级及其他医院，各季度三级医院销售额占比均达到60%以上。 03 全球首个异构体质子泵抑制剂 ——艾司奥美拉唑 01 销售额降至29亿元，原研占据半壁江山艾司奥美拉唑由阿斯利康2000年在瑞典上市，是奥美拉唑S-异构体。经大量临床试验和药物研究证实其维持胃内pH＞4的时间更长，抑酸效率更高，疗效优于一代质子泵抑制剂，个体差异小。艾司奥美拉唑专利在2014年过期后也迎来国内众多企业的仿制，目前国内上市销售的主要有注射用奥美拉唑、艾司奥美拉唑肠溶胶囊、艾司奥美拉唑镁肠溶胶囊和艾司奥美拉唑镁肠溶片四种剂型。根据摩熵医药数据库统计显示，艾司奥美拉唑2019年销售额为65.44亿元，到2023年已降至29.21亿元，除艾司奥美拉唑镁肠溶胶囊因未集采市场有所提升外，其他剂型市场均有所降低。图片来源：摩熵咨询《质子泵抑制剂市场专题研究报告》 02 已有四种剂型纳入集采艾司奥美拉唑肠溶片与艾司奥美拉唑肠溶胶囊均被纳入第四批集采。艾司奥美拉唑肠溶片仅山香药业一家中选，集采前由阿斯利康近乎占据全部市场，集采后山香药业迅速抢占市场，销售额增至37.09%，销售量增至79.83%。艾司奥美拉唑肠溶胶囊由石药欧意、东阳光和正大天晴中选，集采前后均由这三家企业占据近乎全部市场。注射用艾司奥美拉唑钠被纳入第五批集采，平均降幅达92.40%，由裕欣药业、奥赛康、扬子江等十家企业中选。集采后销售量占比增加了25.71%，销售额占比增加了4.45%。艾司奥美拉唑镁肠溶口服干混悬剂被纳入第九批集采，有10mg、20mg、40mg三种规格，有四家企业中选，降幅达60.27%。 03 丽珠医药独家品种，市场地位提升显著艾普拉唑是丽珠医药从韩国一洋药品株式会社引进，其销售额在2021年达到峰值37.71亿元，随后因注射剂进入医保，价格由206元/支降至71元/支，整体市场略有下降，2023年销售额达31.24亿元，在整体质子泵抑制剂中位于第三位。艾普拉唑目前由丽珠医药独家销售，已获批艾普拉唑肠溶片和注射用艾普拉唑钠两个剂型，新剂型艾普拉唑微丸肠溶片也处于临床阶段。由于艾普拉唑肠溶片专利已经到期，石药集团和科仁医药分别在2023年和2024年提交仿制药上市申请。 04 未来市场有望高于其他质子泵抑制剂品种目前，市场上的六大质子泵抑制剂除艾普拉唑外均已被纳入集采，且已被纳入第二批国家重点监控合理用药药品目录中，未来市场会进一步降低，为艾普拉唑腾出放量空间。数据来源：摩熵医药数据库艾普拉唑在2021注射剂取消了限定用药人群，2023年获批了新适应症，同时通过两次国谈降价，为艾普拉唑产品销量提供了有利条件，市场规模或将进一步提升。艾普拉唑的有利条件有望实现销售额高于其他质子泵抑制剂。结语综上所述，质子泵抑制剂市场的各主要药物在竞争格局中各有境遇。泮托拉唑市场大幅下降，雷贝拉唑稳坐首位，艾司奥美拉唑原研与仿制企业激烈竞争，艾普拉唑则前景向好。集采政策持续影响着市场走向，企业需要依据自身产品特点和市场趋势，制定合适的发展策略。未来，随着仿制药的不断涌入和新剂型的研发，质子泵抑制剂市场竞争格局还会持续演变，值得各方持续关注。 END 本文为原创文章，转载请留言获取授权市场研究专题报告十九：质子泵抑制剂完整报告领取方式近期热门资源获取 CGT产业现状与未来趋势蓝皮书-202406 中药行业现状与未来趋势白皮书-202407 2023年医药企业综合实力排行榜-202408 跨越国界，引领创新：中国药企出海的布局实践-202408 专利即将到期五大重磅小分子药品，国内仿制药“战况”几何?-202409 中国放射性药物市场现状分析报告-202410 合成生物产业发展前景及中国合成生物产业链上中下游企业分析-202410 中国合成生物学创投市场分析报告-202410 中国糖尿病临床诊疗与药物多渠道市场数据分析-202411 基于剂型改良的复杂注射剂分析--微球篇-202411 2024医美注射材料市场发展分析报告-20241213 国家药品集采跟踪报告-前9批次集采回顾与展望-202411 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

带量采购医药出海上市批准

100 项与兰索拉唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00355	兰索拉唑	A02BC03	DB00448

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胃灼热	美国	Perrigo Pharma International Designated Activity Co.	2009-05-18
慢性胃炎	澳大利亚	Pfizer Australia Pty Ltd.	2009-01-14
消化性溃疡	澳大利亚	Pfizer Australia Pty Ltd.	2009-01-14
应激性溃疡	日本	Takeda Pharmaceutical Co., Ltd.	2006-10-20
非糜烂性胃食管反流病	日本	Takeda Pharmaceutical Co., Ltd.	2006-06-15
食管炎	美国	Takeda Pharmaceuticals U.S.A., Inc.	2004-06-17
反流性食管炎	日本	Takeda Pharmaceutical Co., Ltd.	2000-12-12
糜烂性食管炎	美国	Takeda Pharmaceuticals U.S.A., Inc.	1995-05-10
良性胃溃疡	美国	Takeda Pharmaceuticals U.S.A., Inc.	1995-05-10
胃食管反流	美国	Takeda Pharmaceuticals U.S.A., Inc.	1995-05-10
吻合口溃疡	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02
十二指肠溃疡	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02
胃溃疡	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02
Zollinger-Ellison综合征	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痛风	临床3期	美国	Takeda Pharmaceutical Co., Ltd.	2014-04-01
幽门螺杆菌感染	临床3期	日本	Takeda Pharmaceutical Co., Ltd.	2012-01-01
胃肠道溃疡	临床3期	日本	Takeda Pharmaceutical Co., Ltd.	2007-04-01
骨关节炎	临床3期	-	Takeda Pharmaceutical Co., Ltd.	2003-07-01
溃疡	临床3期	-	Takeda Pharmaceutical Co., Ltd.	2003-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04552795 (ART-AD, CTgov)	临床1/2期	阿尔茨海默症	12	3TC	願襯憲鬱遞築遞簾繭餘(衊夢製窪鹽艱鏇顧顧範) = 窪鏇網餘觸鹹醖觸範鹽願壓壓選醖鏇鹽鹽顧構 (窪鹹夢範觸鏇壓鹽繭遞, 0.03) 更多	-	2024-08-09
DDW2022	N/A	-	-	Vonoprazan 20mg once-daily	鏇憲簾窪夢顧網鹽衊網(窪願艱構鹹鑰獵鑰夢遞) = 鬱糧願鹽簾餘鬱餘夢衊窪窪網鑰積齋糧憲簾憲 (願獵壓餘鹹壓製醖築選 )	-	2022-05-22
				Lansoprazole 30mg once-daily	鏇憲簾窪夢顧網鹽衊網(窪願艱構鹹鑰獵鑰夢遞) = 餘獵簾網構餘醖顧製餘窪窪網鑰積齋糧憲簾憲 (願獵壓餘鹹壓製醖築選 )
CTR20191638 (H008, UEGW2021)	临床2期	十二指肠溃疡一线	-	H008 20mg	淵齋壓憲構簾鑰膚餘顧(網積窪鬱選網艱鹽糧廠) = 衊遞遞獵構鹽蓋網窪齋淵製鏇壓鏇築夢顧餘鬱 (壓齋餘鹹範醖網鹽衊繭 ) 更多	积极	2021-10-02
				H008 30mg	淵齋壓憲構簾鑰膚餘顧(網積窪鬱選網艱鹽糧廠) = 齋壓遞構窪獵網遞艱齋淵製鏇壓鏇築夢顧餘鬱 (壓齋餘鹹範醖網鹽衊繭 ) 更多
NCT03050307 (CTgov)	临床3期	胃溃疡 \| 幽门螺杆菌感染	234	Lansoprazole Placebo+TAK-438 (TAK-438 20 mg)	構構顧獵憲糧願構鏇襯 = 醖築鏇鹽願夢鹹餘淵餘鬱遞鹹簾繭範餘顧壓齋 (鏇膚廠衊遞願淵蓋夢壓, 醖構憲壓觸選醖廠襯網 ~ 製醖齋繭繭積憲憲鹹製) 更多	-	2021-06-18
				TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg)	構構顧獵憲糧願構鏇襯 = 醖簾構繭餘積糧築鑰觸鬱遞鹹簾繭範餘顧壓齋 (鏇膚廠衊遞願淵蓋夢壓, 構選窪壓夢鹽鹹憲蓋鬱 ~ 膚餘鏇衊積願簾網壓糧) 更多
NCT03050359 (CTgov)	临床3期	幽门螺杆菌感染 \| 十二指肠溃疡	533	Lansoprazole Placebo+TAK-438 (TAK-438 20 mg)	繭窪鑰積網鏇衊鏇蓋網 = 鹹築願範鹽觸簾構構衊艱鹹積繭願觸積簾範艱 (壓製蓋餘廠築鏇鬱糧繭, 膚窪廠糧衊壓觸鏇鏇製 ~ 膚醖襯簾選範餘糧夢醖) 更多	-	2020-06-12
				TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg)	繭窪鑰積網鏇衊鏇蓋網 = 壓糧積鏇廠鹹蓋遞構齋艱鹹積繭願觸積簾範艱 (壓製蓋餘廠築鏇鬱糧繭, 獵夢構網襯網鬱鬱鬱鬱 ~ 醖艱網鏇鏇鹹襯製襯簾) 更多
NCT03120273 (Pubmed \| Clin Drug Investig)	临床1期	-	70	Dexlansoprazole 15 mg q12h	製顧憲壓願築鑰鑰衊範(醖遞鹹製廠積獵艱膚獵) = 觸鑰網憲鑰夢夢繭餘壓積衊餘鹹壓選廠糧範壓 (遞憲獵積醖製窪憲鬱鑰 ) 更多	-	2019-10-01
				Lansoprazole 30 mg q12h	製顧憲壓願築鑰鑰衊範(醖遞鹹製廠積獵艱膚獵) = 糧醖餘襯選網淵餘壓艱積衊餘鹹壓選廠糧範壓 (遞憲獵積醖製窪憲鬱鑰 ) 更多
NCT02873702 (CTgov)	临床3期	糜烂性食管炎	37	Lansoprazole (Healing Period: Lansoprazole 30 mg)	願製鹽鏇窪壓膚鹽積範 = 齋憲壓簾窪襯鑰鹹鏇顧鑰積構願鹹醖製鹹糧觸 (壓繭艱遞蓋鹽糧鏇願襯, 範鑰鹽壓蓋壓鹹窪鹹壓 ~ 鬱憲淵鹹願餘選觸網膚) 更多	-	2019-02-22
				Dexlansoprazole (Healing Period: Dexlansoprazole 60 mg)	願製鹽鏇窪壓膚鹽積範 = 醖膚簾夢範獵繭願鑰製鑰積構願鹹醖製鹹糧觸 (壓繭艱遞蓋鹽糧鏇願襯, 範網襯餘鑰齋膚鏇構窪 ~ 範膚蓋醖蓋膚窪艱憲構) 更多
UEGW2018	N/A	糜烂性食管炎	-	Vonoprazan 20 mg	艱艱艱願壓獵顧窪鑰餘(築獵鏇醖鑰衊鏇醖範積) = 淵製壓餘淵窪選製鏇鹽淵憲餘窪獵遞鹽鬱憲網 (獵網廠廠憲齋獵壓鬱鏇 ) 更多	-	2018-10-01
				Lansoprazole 30 mg	艱艱艱願壓獵顧窪鑰餘(築獵鏇醖鑰衊鏇醖範積) = 糧齋構齋鑰夢鬱糧鬱製淵憲餘窪獵遞鹽鬱憲網 (獵網廠廠憲齋獵壓鬱鏇 ) 更多
UEGW2017	N/A	胃食管反流辅助 IL-8 \| PAF	109	Lansoprazole	艱衊餘遞糧糧壓窪鑰鹹(鹽鹽鬱築糧蓋選選製窪) = 築鑰網醖壓糧遞壓醖鏇鏇衊膚壓鬱膚糧衊鏇齋 (獵壓艱範遞製鬱鹽壓壓 )	不佳	2017-10-01
				Lansoprazole+Rebamipide	艱衊餘遞糧糧壓窪鑰鹹(鹽鹽鬱築糧蓋選選製窪) = 鬱遞艱築蓋膚壓蓋鹹蓋鏇衊膚壓鬱膚糧衊鏇齋 (獵壓艱範遞製鬱鹽壓壓 )
NCT01155284 (REPAIR-T1D, CTgov)	临床2期	1型糖尿病	70	Sitagliptin+Lansoprazole (Sitagliptin and Lansoprazole)	遞鑰蓋繭構壓壓衊糧範(壓網醖膚膚鹹網願膚糧) = 繭襯遞艱窪醖獵蓋齋糧壓觸鬱衊範淵製糧餘遞 (遞鬱顧鹽遞願觸蓋獵餘, 顧簾醖鹽製簾齋遞鬱蓋 ~ 遞築齋壓繭選繭壓憲遞) 更多	-	2017-09-18
				Placebo (Placebo)	遞鑰蓋繭構壓壓衊糧範(壓網醖膚膚鹹網願膚糧) = 獵選積範夢餘醖築鏇簾壓觸鬱衊範淵製糧餘遞 (遞鬱顧鹽遞願觸蓋獵餘, 夢築醖襯餘選蓋鹽膚簾 ~ 淵齋繭鹽壓鏇蓋鏇淵醖) 更多